November 17, 2021 @ 12:00 pm – 1:00 pm
Twogether Consulting is happy to have Sunovion Pharmaceuticals again as resource for IDD providers in our free webinar series this month.
Free Webinar Series Hosted By: Sunovion Pharmaceuticals
Pre-Registration is Required!!
or Visit www.neurologyprograms.com/webcast
to REGISTER to attend this program.
Meeting code: 208438
Ph: 530-864-3119 (Please contact Mr. James if you need any assistance with registration or additional information!)
Nanette Wrobel, RPh
Director of Education/Business Development
Tarrytown Expocare Pharmacy
APTIOM “A Treatment Option for the Management of Focal Seizures in Adults”
Treatment Considerations for Patients in Long-term Care, Including Those With Intellectual and Developmental Disabilities
This presentation reviews epilepsy in adults with intellectual and developmental disabilities, elderly individuals, and residents of long-term care settings, focusing on prevalence, key diagnostic challenges, and factors impacting treatment. It also provides an overview of APTIOM adjunctive therapy in adults with focal seizures and details the Phase III randomized, double-blind, placebo-controlled clinical trials as well as real-world evidence from the Phase IV open-label clinical trial. The overview covers the product’s indication, efficacy, dosing and administration, safety/tolerability data, and Important Safety Information.
Audience: Intended for audiences who treat adult patients
Nanette Wrobel- Director of Education/Business Development for Tarrytown Pharmacy will be presenting information on the drug treatment, Aptiom, and the possible benefits for individuals in ICF facilities or other programs with Group Home Settings (Includes HCS or DD waiver program in other states), who have focul seizures.
CONNECT WITH THE KEY LEADERS IN THE FIELD OF NEUROLOGY TO HEAR THE LATEST SCIENTIFIC INFORMATION ABOUT APTIOM
This promotional, non-CME program is intended for US health care professionals involved in the treatment of patients 4 years of age and older with partial-onset seizures.
**The speaker is a paid consultant of and is speaking on behalf of
Sunovion Pharmaceuticals Inc.
You may contact us directly as well if you prefer for assistance with registration at: meghanjones.tx.com or Ph: 361-649-5104